Hospital
Havasu Regional Medical Center LLC
Havasu Regional Medical Center LLC was paid $23.19M by Medicaid between Jan 2018 and Dec 2024, across 244 billing codes. Its largest line is 99284, emergency room visit (serious) — 20% of everything it billed.
33Billing provider infoHAVASU REGIONAL MEDICAL CENTER LLC
LAKE HAVASU CITY, AZ 86403
LAKE HAVASU CITY, AZ 86403
33aNPI1780761866assigned 11/01/2006
33bProvider typeRural Acute Care Hospital
28Total paid$23.19M
24GClaims548,978
24DCodes billed244
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in Arizona
Rank by total paid#3 of 5
Median peer was paid$23.19M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 104,042 | $3.70M | |
| 2019 | 92,659 | $3.97M | |
| 2020 | 70,798 | $3.58M | |
| 2021 | 85,106 | $3.76M | |
| 2022 | 77,844 | $3.14M | |
| 2023 | 68,926 | $2.92M | |
| 2024incomplete | 49,603 | $2.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 20,363 | 18,039 | $4.70M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 13% | 5,194 | 4,621 | $3.08M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 14,840 | 13,631 | $2.88M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 9.3% | 891 | 788 | $2.15M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.9% | 10,756 | 8,761 | $1.83M |
| G0378 | Hospital observation service, per hour | 6.2% | 6,852 | 4,015 | $1.44M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 4.5% | 4,492 | 1,729 | $1.04M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.3% | 5,459 | 4,723 | $986K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.8% | 1,864 | 1,722 | $873K |
| 72125 | Computed tomography, cervical spine; without contrast material | 2.6% | 2,368 | 2,101 | $605K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 2.6% | 2,147 | 1,895 | $601K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 4,389 | 4,161 | $478K |
232 more codes
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.6% | 3,231 | $378K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,769 | $220K |
| 80053 | Comprehensive metabolic panel | <1% | 8,926 | $198K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,483 | $194K |
| 93971 | <1% | 635 | $132K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 162 | $109K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 26 | $95K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,826 | $90K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,446 | $87K |
| 76641 | <1% | 578 | $78K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,819 | $56K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 85 | $56K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 119 | $46K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 719 | $43K |
| 72100 | <1% | 667 | $29K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 74 | $28K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,443 | $27K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,794 | $23K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 144 | $22K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 176 | $21K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,982 | $21K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,123 | $20K |
| 77080 | <1% | 197 | $20K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 28,124 | $20K |
| 80076 | <1% | 20,866 | $19K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 548 | $19K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 234 | $19K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,707 | $17K |
| 73030 | <1% | 921 | $17K | |
| 71045 | Radiologic examination, chest; single view | <1% | 10,401 | $17K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 216 | $17K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 705 | $17K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 325 | $16K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 8,900 | $16K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,037 | $15K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 36,989 | $15K |
| 73562 | <1% | 622 | $13K | |
| 72131 | <1% | 59 | $13K | |
| 73110 | <1% | 259 | $12K | |
| 77066 | Tomosynthesis, mammo | <1% | 130 | $11K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,161 | $10K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 40 | $9K |
| 71250 | <1% | 155 | $9K | |
| 73130 | <1% | 769 | $9K | |
| 73610 | <1% | 649 | $9K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,541 | $8K |
| 74022 | <1% | 113 | $8K | |
| 84484 | <1% | 8,733 | $8K | |
| 72110 | <1% | 78 | $8K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,479 | $7K |
| 73630 | <1% | 818 | $7K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 570 | $6K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,489 | $6K |
| 82803 | <1% | 766 | $6K | |
| 74018 | <1% | 406 | $6K | |
| 73502 | <1% | 505 | $6K | |
| 82077 | <1% | 2,187 | $5K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 174 | $5K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 158 | $5K |
| 0450 | Emergency room services | <1% | 117 | $5K |
| 97161 | <1% | 312 | $4K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 56 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,307 | $4K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 272 | $4K |
| 87040 | <1% | 2,665 | $3K | |
| 87186 | <1% | 1,758 | $3K | |
| 83690 | <1% | 9,973 | $3K | |
| 83735 | <1% | 7,418 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,533 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,263 | $3K |
| 72170 | <1% | 125 | $3K | |
| 90715 | <1% | 871 | $2K | |
| 85610 | <1% | 7,368 | $2K | |
| 83880 | <1% | 2,236 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,230 | $2K |
| 82728 | <1% | 692 | $2K | |
| 0240U | <1% | 613 | $2K | |
| 85730 | <1% | 4,731 | $2K | |
| 81003 | <1% | 18,208 | $2K | |
| 59025 | Fetal non-stress test | <1% | 877 | $2K |
| 84703 | <1% | 4,124 | $2K | |
| 85379 | <1% | 1,836 | $2K | |
| 86140 | <1% | 2,041 | $2K | |
| 87430 | <1% | 2,010 | $2K | |
| 83605 | <1% | 3,880 | $2K | |
| 84702 | <1% | 852 | $2K | |
| 76770 | <1% | 60 | $2K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 153 | $2K |
| 87070 | <1% | 1,239 | $2K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 12 | $1K |
| 74019 | <1% | 40 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 368 | $1K |
| 80061 | Lipid panel | <1% | 2,163 | $1K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 14 | $1K |
| 81025 | <1% | 3,572 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,652 | $1K |
| 76818 | <1% | 16 | $1K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 624 | $1K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 675 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,760 | $1K |
| 85045 | <1% | 10,166 | $1K | |
| 87081 | <1% | 2,009 | $1K | |
| 86900 | <1% | 2,688 | $845.89 | |
| 76830 | Ultrasound, transvaginal | <1% | 79 | $794.35 |
| C1769 | Guide wire | <1% | 190 | $783.53 |
| 0011A | <1% | 36 | $773.06 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,212 | $765.76 |
| 86850 | <1% | 2,333 | $759.78 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,434 | $755.41 |
| 80143 | <1% | 43 | $728.88 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 1,553 | $714.39 |
| 84100 | <1% | 1,478 | $677.56 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 16 | $648.16 |
| 84439 | <1% | 1,299 | $627.03 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,792 | $624.65 |
| 96376 | <1% | 2,072 | $620.44 | |
| 84145 | <1% | 2,258 | $616.73 | |
| 87077 | <1% | 2,438 | $614.86 | |
| 82247 | <1% | 52 | $593.20 | |
| 82962 | <1% | 7,046 | $577.25 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,256 | $574.13 |
| 82248 | <1% | 1,472 | $551.22 | |
| 86901 | <1% | 2,697 | $512.85 | |
| 80179 | <1% | 55 | $512.46 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,045 | $510.62 |
| 0012A | <1% | 22 | $477.63 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 146 | $437.94 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 38 | $421.74 |
| 72040 | <1% | 15 | $409.62 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 176 | $391.13 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,147 | $384.46 |
| 81001 | <1% | 2,101 | $370.06 | |
| 85027 | <1% | 589 | $356.91 | |
| 96523 | <1% | 15 | $341.07 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,589 | $336.53 |
| 76801 | <1% | 88 | $334.53 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,341 | $300.23 |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,887 | $296.78 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 64 | $290.75 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 134 | $278.43 |
| 82140 | <1% | 229 | $270.00 | |
| 73090 | <1% | 29 | $224.16 | |
| 97165 | <1% | 40 | $223.00 | |
| 87807 | <1% | 927 | $220.32 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,230 | $197.14 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,575 | $182.60 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 8,540 | $161.07 |
| 12001 | <1% | 55 | $158.61 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,070 | $157.78 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 26 | $156.00 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 70 | $152.90 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,626 | $144.93 |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 22 | $140.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 213 | $123.15 |
| 82550 | <1% | 489 | $119.69 | |
| 84132 | <1% | 225 | $119.68 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 389 | $109.05 |
| 84030 | <1% | 57 | $95.84 | |
| 85651 | <1% | 593 | $87.19 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 834 | $82.29 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,832 | $81.55 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,037 | $72.02 |
| 82607 | <1% | 60 | $71.02 | |
| 73080 | <1% | 14 | $69.93 | |
| J1815 | Injection, insulin, per 5 units | <1% | 268 | $67.74 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 109 | $63.86 |
| 96367 | <1% | 701 | $62.10 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,103 | $59.35 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,521 | $55.59 |
| J2704 | Injection, propofol, 10 mg | <1% | 4,298 | $50.52 |
| 99152 | <1% | 494 | $46.65 | |
| 87205 | <1% | 654 | $44.20 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,459 | $41.35 |
| 36600 | <1% | 404 | $34.12 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 612 | $31.93 |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,322 | $30.26 |
| 87075 | <1% | 17 | $28.62 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,010 | $27.22 |
| 87210 | <1% | 90 | $26.83 | |
| 99000 | <1% | 13 | $22.77 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 653 | $17.00 |
| 83540 | <1% | 239 | $16.38 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 626 | $15.74 |
| 83615 | <1% | 37 | $10.90 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 85 | $8.10 |
| 82570 | <1% | 28 | $6.51 | |
| A9270 | Non-covered item or service | <1% | 1,316 | $5.26 |
| 84550 | <1% | 46 | $2.91 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 50 | $1.46 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 123 | $1.26 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 113 | $0.10 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 89 | $0.00 |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | 0% | 203 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 221 | $0.00 |
| 85007 | 0% | 66 | $0.00 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 57 | $0.00 |
| 90670 | 0% | 75 | $0.00 | |
| 90461 | 0% | 68 | $0.00 | |
| 76000 | 0% | 65 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 48 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 16 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 77 | $0.00 |
| 97116 | 0% | 148 | $0.00 | |
| 73590 | 0% | 16 | $0.00 | |
| 82565 | 0% | 17 | $0.00 | |
| 99203 | Doctor's office visit, new patient (routine) | 0% | 18 | $0.00 |
| 84112 | 0% | 13 | $0.00 | |
| 76937 | 0% | 12 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 310 | $0.00 |
| 88304 | 0% | 15 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 85 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 161 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 30 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 106 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 353 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 12 | $0.00 |
| 83550 | 0% | 51 | $0.00 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 47 | $0.00 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 54 | $0.00 |
| 90698 | 0% | 47 | $0.00 | |
| 94760 | 0% | 13 | $0.00 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 43 | $0.00 |
| G0238 | Therapeutic procedures to improve respiratory function, other than described by g0237, one on one, face to face, per 15 minutes (includes monitoring) | 0% | 20 | $0.00 |
| 90744 | 0% | 29 | $0.00 | |
| 36416 | 0% | 17 | $0.00 | |
| 90656 | 0% | 25 | $0.00 | |
| 91301 | 0% | 15 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 15 | $0.00 |
| 88300 | 0% | 12 | $0.00 | |
| C9399 | Unclassified drugs or biologicals | 0% | 46 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 15 | $0.00 |
| 88307 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.